NEW YORK (GenomeWeb News) — Vermillion has licensed a biomarker panel from Stanford University that could be used to assess the risk of peripheral artery disease, the company said today.
 
The agreement gives Vermillion exclusive rights to develop and commercialize a blood-based PAD test, which would use the multi-marker panel to stratify individual risk for developing the disease.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.